Skip to main content
OpenTrials
Completed

NCT Number: NCT04376840

Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19

Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions.

Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function.

Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe SARS-CoV2 Pneumonia Infections Lung Diseases Pneumonia Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Damien JOLLY

Reims, France

About this study

Objective is to evaluate prevalence of long-term respiratory complications after severe SARS-CoV2 pneumonia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patient
  • Patient with with severe SARS-CoV2 pneumonia
  • Patient consenting to participate to the study
  • Patient enrolled in the national healthcare insurance program

Exclusion criteria

  • Patient under 18 years

Treatment and study plan

Blood sample and data record

Other

Blood sample and data record

Primary outcomes

  1. medium-term respiratory complications

    Time frame: 3 months

    Interstitial lung disease diagnosed with a thoracic CT-scan

Secondary outcomes

  1. long-term respiratory complications

    Time frame: 12 months

    Interstitial lung disease diagnosed with a thoracic CT-scan

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
May 6, 2020
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.